Table 2 Clinical trials of ADCs in combination with other anticancer drugs
From: Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Anticancer drugs | Target | NCT number | Drug | Partner drugs/RT type | Phase | Start | Treatment setting | Efficacy |
|---|---|---|---|---|---|---|---|---|
Chemotherapy | HER2 | NCT01702558 | T-DM1 | Capecitabine | I | 2012 | mBC, mGC | Negative |
|  |  | NCT02073916 | T-DM1 | Lapatinib + Abraxane | I | 2013 | mBC | Positive |
|  |  | NCT02073487 | T-DM1 | Lapatinib + Abraxane | II | 2014 | Neoadjuvant, BC | Positive |
| Â | Â | NCT02562378 | T-DM1 | Nonpegylated Liposomal Doxorubicin | I | 2015 | mBC | Negative |
| Â | Â | NCT03190967 | T-DM1 | TMZ | I/II | 2017 | mBC | Terminated |
| Â | Â | NCT04686305 | T-DXd | Durvalumab and Cisplatin | Ib | 2020 | mNSCLC | NA |
|  | TROP2 | NCT05687266 | Datopotamab deruxtecan | Durvalumab + Carboplatin | III | 2022 | mNSCLC | NA |
| Â | Nectin-4 | NCT03288545 | Enfortumab vedotin | Pembrolizumab | I/II | 2017 | mUC | Positive |
|  | TF | NCT03485209 | Tisotumab Vedotin | Pembrolizumab + (Carboplatin or DDP) | II | 2018 | Advanced solid tumors | NA |
| Â | EGFR | NCT02573324 | Depatuxizumab Mafodotin | TMZ and Radiation | III | 2015 | GBM | Positive |
| Â | NaPi2b | NCT04907968 | Upifitamab Rilsodotin | Carboplatin | I | 2021 | High grade serous ovarian cancer | Terminated |
|  | FRα | NCT02606305 | Mirvetuximab Soravtansine | Bevacizumab | Ib/II | 2022 | High-grade epithelial ovarian | Positive |
Endocrine therapy | HER2 | NCT01772472 | T-DM1 | Unspecified | III | 2013 | Adjuvant, BC | Positive |
| Â | Â | NCT04556773 | T-DXd | Anastrozole or Fulvestrant | Ib | 2020 | mBC | NA |
| Â | Â | NCT04553770 | T-DXd | Anastrozole | II | 2020 | Neoadjuvant, BC | NA |
| Â | HER3 | NCT05569811 | Patritumab deruxtecan | Letrozole | II | 2022 | Neoadjuvant, BC | NA |
Radiotherapy |  | NCT01196052 | T-DM1 ± Trastuzumab | CFRT | II | 2010 | HER2 + early-stage BC | NA |
|  |  | NCT01772472 | T-DM1 | CFRT | III | 2013 | HER2 + early BC | Positive |
|  |  | NCT02573324 | TMZ + Depatux-m | CFRT | III | 2015 | EGFR-amplification newly diagnosed GBM | Negative |
|  |  | NCT02590263 | TMZ + Depatux-m | CFRT | I/II | 2015 | EGFR-amplification grade III/IV glioma | NA |
|  |  | NCT05979740 | RC48 + PD-1 | CFRT | II | 2023 | MIBRC with high HER2+ | NA |
Targeted therapy | HER2 | NCT01120184 | T-DM1 | Pertuzumab | III | 2010 | mBC | Positive |
| Â | Â | NCT03225937 | T-DM1 | Pertuzumab | II | 2012 | mCRC | Negative |
|  |  | NCT02073916 | T-DM1 | Lapatinib + Abraxane | I | 2013 | mBC | Positive |
| Â | Â | NCT01983501 | T-DM1 | Tucatinib | Ib | 2014 | mBC | Positive |
| Â | Â | NCT02038010 | T-DM1 | BYL719 (alpelisib) | I | 2014 | mBC | Positive |
|  |  | NCT02073487 | T-DM1 | Lapatinib + Abraxane | II | 2014 | Neoadjuvant, BC | Positive |
| Â | Â | NCT02657343 | T-DM1 | Ribociclib | Ib/II | 2016 | mBC | Negative |
| Â | Â | NCT03364348 | T-DM1 | Utomilumab | I | 2017 | mBC | NA |
| Â | Â | NCT03523572 | T-DXd | Nivolumab | I | 2018 | mBC & mUC | Positive |
| Â | Â | NCT04042701 | T-DXd | Pembrolizumab | I | 2019 | mBC & mNSCLC | NA |
| Â | Â | NCT03975647 | T-DM1 | Tucatinib | III | 2019 | mBC | NA |
| Â | Â | NCT04264936 | RC48 | Toripalimab (JS001) | Ib/II | 2020 | mUC | Positive |
| Â | Â | NCT04235101 | (Vic-)trastuzumab duocarmazine | Niraparib | I | 2020 | Advanced solid tumors | NA |
| Â | Â | NCT04538742 | T-DXd | Pertuzumab | Ib/II | 2020 | mBC | NA |
| Â | Â | NCT04556773 | T-DXd | Anastrozole | Ib/II | 2020 | mBC | NA |
| Â | Â | NCT04539938 | T-DXd | Tucatinib | II | 2020 | mBC | NA |
|  |  | NCT04197687 | T-DM1 | TPIV100 + Sargramostim | II | 2020 | Adjuvant BC | NA |
| Â | Â | NCT04704661 | T-DXd | AZD6738 | I | 2021 | Advanced solid tumors | NA |
|  |  | NCT04983121 | ARX788 | Pyrotinib Maleate | II | 2021 | Neoadjuvant, BC | NA |
| Â | Â | NCT04585958 | T-DXd | Olaparib | I | 2021 | mEC | NA |
| Â | Â | NCT05372614 | T-DXd | Neratinib | I | 2022 | Advanced solid tumors | NA |
|  |  | NCT05426486 | ARX788 | Pyrotinib | II/III | 2022 | Neoadjuvant, BC | NA |
| Â | Â | NCT05868226 | T-DXd | ALX148 | I | 2022 | mBC | NA |
| Â | TROP2 | NCT04039230 | sg | Talazoparib | I/II | 2019 | mBC | Positive |
|  |  | NCT04381832 | SG | Etrumadenant + Zimberelimab | I/II | 2020 | mCRPC | NA |
| Â | Â | NCT05143229 | SG | Alpelisib | I | 2021 | mBC | NA |
| Â | Â | NCT05006794 | SG | GS9716 | I | 2021 | Advanced solid tumors | NA |
| Â | Â | NCT05575804 | GQ1001 | Pyrotinib | I/II | 2022 | mBC | NA |
| Â | Nectin-4 | NCT04724018 | EV | SG | I | 2021 | mUC | NA |
| Â | Â | NCT04878029 | EV | Cabozantinib | I | 2021 | mUC | NA |
| Â | Â | NCT03606174 | EV | Sitravatinib | II | 2018 | mUC | NA |
| Â | Â | NCT04963153 | EV | Erdafitinib | I | 2021 | Metastatic bladder cancer | NA |
|  | FRα | NCT05200364 | STRO-002 | BEV | I | 2022 | Advanced epithelial ovarian cancer | NA |
| Â | Â | NCT05445778 | Mirvetuximab soravtansine | BEV | III | 2022 | Advanced epithelial ovarian cancer | NA |
| Â | MET | NCT02099058 | Telisotuzumab | Osimertinib | I/Ib | 2014 | Advanced solid tumors | NA |
| Â | EGFR-cMET bispecific | NCT05647122 | AZD9592 | Osimertinib | I | 2022 | Advanced solid tumors | NA |
| Â | LIV-1 | NCT01969643 | Ladiratuzumab vedotin | Trastuzumab | I | 2013 | mBC | NA |
| Â | B7-H3 | NCT05293496 | MGC018 | Lorigerlimab | I | 2022 | Advanced solid tumors | NA |
Immunotherapy | HER2 | NCT02605915 | T-DM1 | Atezolizumab | Ib | 2015 | mBC | Positive |
| Â | Â | NCT02924883 | T-DM1 | Atezolizumab | II | 2016 | mBC | Negative |
| Â | Â | NCT03364348 | T-DM1 | Utomilumab | IB | 2017 | mBC | NA |
| Â | Â | NCT0303210 | T-DM1 | Pembrolizumab | Ib | 2017 | mBC | NA |
| Â | Â | NCT03523572 | T-DXd | Nivolumab | Ib | 2018 | mBC & mUC | Positive |
| Â | Â | NCT04042701 | T-DXd | Pembrolizumab | Ib | 2019 | mBC & mNSCLC | NA |
| Â | Â | NCT05480384 | T-DXd | Nivolumab | II | 2022 | Esophagogastric adenocarcinoma | NA |
| Â | Â | NCT04264936 | RC48 | Toripalimab | Ib/II | 2020 | mUC | Positive |
| Â | Â | NCT0446046 | SBT6050 | Pembrolizumab | I | 2020 | Advanced solid tumors | Positive |
| Â | Â | NCT0511345 | RC48 | Sintilimab and Capecitabine | II | 2021 | Neoadjuvant, GC | NA |
| Â | Â | NCT04879329 | RC48 | Pembrolizumab | II | 2021 | mUC | NA |
| Â | Â | NCT05016973 | RC48 | Triplizumab | II | 2021 | Neoadjuvant, MIBC | NA |
| Â | Â | NCT04873362 | T-DM1 | Atezolizumab | III | 2021 | Adjuvant, BC | NA |
| Â | Â | NCT04740918 | T-DM1 | Atezolizumab | III | 2021 | mBC | NA |
| Â | Â | NCT05488353 | RC48 | Penpulimab Injection | NA | 2022 | Neoadjuvant, bladder urothelial carcinoma | NA |
| Â | Â | NCT05495724 | RC48 | Tislelizumab | II | 2022 | Bladder cancer | NA |
| Â | Â | NCT05493683 | RC48 | Tislelizumab | II | 2022 | mCRC | NA |
| Â | Â | NCT05333809 | RC48 | Pembrolizumab | II | 2022 | mCRC | NA |
|  |  | NCT05313906 | RC48 | AK105 + Cisplatin | II | 2022 | mGC | NA |
| Â | Â | NCT05417230 | RC48 | Envafolimab | II | 2022 | mBTC | NA |
| Â | Â | NCT05115500 | RC48 | Hypofractionated RT, PD-1/PD-L1 inhibitor | II | 2022 | Advanced solid tumors | NA |
| Â | Â | NCT05297552 | RC48 | Toripalimab | II | 2022 | Â | NA |
| Â | Â | NCT05302284 | RC48 | Toripalimab | III | 2022 | mUC | NA |
| Â | Â | NCT05320588 | BIO-106 | Pembrolizumab | I/II | 2022 | Advanced solid tumors | NA |
|  |  | NCT05514158 | RC48 | Chemotherapy + Nivolumab RC98 | I | 2022 | mGC | NA |
|  |  | NCT05979740 | RC48 | Toripalimab + RT | II | 2023 | MIBC | NA |
| Â | TROP2 | NCT03742102 | T-DXd, | Durvalumab | IB/II | 2018 | mBC | Positive |
| Â | Â | NCT03337698 | SG | Atezolizumab | Ib/II | 2017 | mNSCLC | NA |
| Â | Â | NCT03424005 | SG | Atezolizumab | Ib/II | 2018 | mBC | NA |
| Â | Â | NCT03971409 | SG | Avelumab | II | 2019 | mBC | NA |
| Â | Â | NCT03869190 | SG | Atezolizumab | Ib/II | 2019 | mUC | NA |
| Â | Â | NCT04434040 | SG | Atezolizumab | II | 2020 | Adjuvant, BC | NA |
| Â | Â | NCT04468061 | SG | Pembrolizumab | II | 2020 | mBC | NA |
| Â | Â | NCT04448886 | SG | Pembrolizumab | II | 2020 | mBC | NA |
|  |  | NCT04381832 | SG | Etrumadenant + Zimberelimab | I/II | 2020 | mCRPC | Positive |
| Â | Â | NCT04863885 | SG | IPI-NIVO | I/II | 2021 | mUC | Positive |
| Â | Â | NCT05382286 | SG | Pembrolizumab | III | 2022 | mBC | NA |
| Â | Â | NCT05186974 | SG | Pembrolizumab and a platinum agent | II | 2022 | mNSCLC | NA |
| Â | Â | NCT05327530 | SG | Avelumab | II | 2022 | mUC | NA |
|  |  | NCT05687266 | Dato-DXd | Durvalumab + Carboplatin | III | 2022 | mNSCLC | NA |
|  |  | NCT05489211 | Dato-Dxd | Durvalumab + AZD5305 | II | 2022 | Advanced solid tumors | NA |
| Â | Â | NCT04526691 | Dato-Dxd | Pembrolizumab | I | 2020 | Advanced or metastatic NSCLC | Positive |
| Â | Â | NCT04612751 | Dato-Dxd | Durvalumab AZD2936 MEDI5752 | Ib | 2020 | Advanced or metastatic NSCLC | NA |
| Â | Â | NCT05941507 | LCB84 | Anti-PD-1 | I/II | 2023 | Advanced solid tumors | NA |
| Â | Nectin-4 | NCT03924895 | EV | Pembrolizumab | III | 2019 | Perioperative, MIBC | NA |
|  |  | NCT04223856 | EV | Pembrolizumab + Cisplatin or Carboplatin | III | 2020 | mUC | Positive |
| Â | Â | NCT04700124 | EV | Pembrolizumab | III | 2021 | Perioperative, MIBC | NA |
| Â | Â | NCT05239624 | EV | Pembrolizumab | II | 2022 | Neoadjuvant, UC | NA |
| Â | Â | NCT05756569 | EV | Pembrolizumab | II | 2023 | mUC | NA |
| Â | Â | NCT05775471 | EV | Pembrolizumab | II | 2023 | Upper tract urothelial cancer | NA |
| Â | EGFR | NCT04305795 | ASP-1929 | Pembrolizumab Cemiplimab | I/II | 2020 | Advanced solid tumors | NA |
| Â | Â | NCT05265013 | ASP-1929 | Pembrolizumab | II | 2022 | Locoregional recurrent SCCHNC | NA |
| Â | ROR2 | NCT03504488 | CAB-ROR2-ADC | PD-1 inhibitor | I/II | 2018 | Advanced solid tumors | NA |
|  | FRα | NCT02606305 | Elahere | Pembrolizumab | Ib/II | 2022 | Epithelial ovarian | NA |
| Â | Â | NCT03835819 | Elahere | Pembrolizumab | II | 2019 | mEC | NA |
| Â | AXL | NCT03425279 | CAB-AXL-ADC | PD-1 inhibitor | I/II | 2018 | Advanced, refractory sarcoma | NA |
| Â | Â | NCT04681131 | CAB-AXL-ADC | PD-1 inhibitor | II | 2021 | mNSCLC | NA |